Digital health innovations
We are actively seeking proven digital innovations that improve the health of people in the region and raise the quality, efficiency, safety and cost-effectiveness of delivering healthcare.
We are particularly interested to hear about innovations in the following categories:
  • Health maintenance - supporting people in maintaining their physical and mental wellbeing,
  • Prevention - alerting patients, carers or professionals when there are signs that things aren’t going well, and an intervention can prevent crises or emergencies
  • Access - providing more convenient and cost-effective ways for patients and professionals to interact. (e.g. remote monitoring or virtual consultations).
  • Learning and education - delivering information and knowledge to patients about their health or condition, or to professionals to support their continuous professional development
  • Pathways - providing tailored information to patients, carers and professionals on services to signpost people to the most appropriate place.  Ideally, this could be enhanced with real-time information about capacity.
  • Research - using digital tools to promote involvement in research & clinical trials, to streamline the capture of informed consent, and to capture research data more efficiently and conveniently.
  • Integration - tools that enable the secure, appropriate sharing of information between organisations (e.g. GPs and hospital clinicians) and sectors (e.g. NHS and Social Services) to allow patients to receive seamless care.
  • Data Visualisation - innovative ways of presenting information in a meaningful way to enable more informed decisions by patients and professionals.  This may involve aggregating data from different sources, reporting tools or graphic visualisations such as heat maps.

Ideas (Publish, Detailed Submission)

Innovation 'Elevator Pitch':
Using pathways and simulations to generate a synthetic population, informed by known population and health statistics, to act as a safe and effective testing environment for digital health solutions.
Overview of Innovation:
We are using pathways and simulations to generate a synthetic population, informed by known population and health statistics. This is intended to act as a testing environment, providing evidence for the decision-making, implementation and evaluation of all policies that impact health, whilst eliminating the risk of using real patient data.

The process involves conducting a document analysis on relevant documents, clinical guidelines and standards to set the scope of the project and identify the important information items that need to included in the model. Existing pathways can be used or, based on evidence from the document analysis, new pathways created to include care, disease progression or system management pathways. A synthethic population is then generated using Census data for the specific locality, to reflect the same demographic distributions of the real population. This population are then run through the pathways and at each clinical interaction on the pathway, a digital exhaust can be produced that reflects those seen in real systems. The pathway execution stage also produces an event log detailing the steps and relevant information (e.g. costs and waiting times) for each individual in the population. These outputs can then be analysed using data visualisation tools to provide an interactive dashboard that visually tracks, analyzes and displays they key performance indicators (KPI), metrics or key data points needed for the project.

This approach can be used to support service design, business case development, clinical engagement, user prototyping, supplier testing, training, demonstration, software product testing and resources for hackathon events.

This is a scalable and reusable approach that will be of particular value following the implementation of the GPDR in May 2018 when anyone interested in data-driven improvements for health will need synthetic data.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
This approach has many valuable use cases for the NHS, including:
  1. Service design 
    • Building pathways in a standard format and using a realistic synthethic population, the workload, outcomes and risk factors affecting the service can be illustrated and reviewed
  2. Business case development 
    • Running the model twice, once with and once without a planned service change, allows the delivery, benefits and risks of a new service to be monitored
  3. Clinical engagement 
    • Engaging pathway diagrams and credible synthetic health records bring a project and the use case to life, helping to engage clinicians throughout a project, enabling issues and misunderstandings to be identified and resolved early
  4. User prototyping
    • Providing realistic data for early prototype screens and documents to verify user needs and set expectations will facilitate an easier, quicker and cheaper process of iteratively building, testing and adapting ideas
  5. Supplier testing
    • Providing an extensive set of synthetic data is able to simulate a wide range of scenarios for system testing, without using real patient data that has privacy restrictions
  6. Training 
    • Generating live synthetic data that is close to the real population in terms of age/sex/household composition/clinical history can be used to train clinicians on how to use the current systems, without using real patient data
  7. Demonstration
    • Using a population and clinical pathways that are relevant to the specific customer is more engaging and better for demonstrating the value of the product for the clients use case
  8. Software product testing
    • Synthetic data, that replicates real patient data but is free from privacy restrictions, can be generated to provide software developers with a rich testing framework, allowing them to build, test and improve their products before deployment
  9. Hackathon resources
    • Providing a synthetic population and library of pathways prior to an event will help to set the scope of the hackathon
    • A toolkit to generate relevant test data can then also support projects that emerge during the hackthon, improving the productivity and value of these events
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
This approach will improve the safety and efficiency of patient care in the health service in the West Midlands, support interoperability and innovation and ensure patient data is protected from privacy and confidentiality issues. This will have a huge range of benefits for the West Midlands population, from better care to more control over the use of their data.
Current and planned activity: 
We currently have two proof-of-concepts projects;
  1. Supporting a business case for a Fracture Liaison Service 
  2. Generating the FHIR resources and profiles for a synthethic population of asthma patients
We are looking for research partners or Trusts interested in putting together a joint-bid for some EU funding to explore and assess the technical feasibility and commercial potential of this approach. We would also be interested in working on individual use cases with digital leads or with standards development organisations to develop this as a system-wide approach.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Allie Short 19/03/2018 - 16:29 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ISL has recently developed a Clinical Trial platform that could be used for collaboration by multiple institutions including NHS/Academia/Pharma/Industry.  Shared protocols, intelligent workflows and secure data management underpin the solution.
Overview of Innovation:
Ensuring your data is accurate, your samples are viable and your results are verifiable are essential when managing clinical trials and carrying out research.

Achiever Medical provides your laboratory with the functionality to manage data quality and integrity, an audit trail to help you assess the quality of your samples and a workflow tool to help map your processes into the solution, including managing the approvals process.

  • Clinical trial functionality to allow easy adoption and customisation for launching and building up clinical trial datasets
  • Manage cohorts, studies, samples, visits and results within a single system that can be shared amongst all collaborating parties
  • One system across multiple institutes, pharma, industry and academia
  • Management reporting cross centre
  • Create and deliver trials quickly with customised data requirements
  • Enforce trial protocols to promote quality and single approach
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
  • Rapid rollout of system to support data capture of clinical trials
  • Modify processes and protocols per clinical trial with minimal recourse to IT
  • Share data regionally/nationally across trials
  • Role based permissions to protect data
  • Single system to administer
  • Adapt processes and protocols for trials quickly
Assess Sample Viability
Ensuring you are carrying out research on viable samples is essential when validating any results.  Achiever provides a comprehensive audit trail against each sample including complete details of storage location history (with a temperature audit),  sample check out history (when, by whom, how long and for what purpose) and sample processing history (with sample collection date/time, processed date/time).  A complete sample family history is also available for managing aliquots with related samples (including parent) accessible with a single click.
 
Maintaining Confidentiality
Confidentiality is not only critical when handling patient information but is also a legal requirement.  Achiever offers flexible, secure data protection options to restrict access to identifiable and sensitive information to authorised users only.  Data encryption routines encrypt data at source whilst data security filters only allow authorised users access to selected information within the system.
 
Managing Studies and Workloads
Define studies within the Achiever system and link team members along with their relevant roles.  Generate activities to create and manage workloads with a graphical calendar available to view team schedules.  Monitor and track equipment and consumables used. Capture analyses and results along with any associated documentation and images.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
  • Make clinical trials available quickly to patients within the WM region
  • Ease of reporting to present efficacy of trial within the region
  • Show proactivity of centres and success in recruiting potential volunteers for trial
Current and planned activity: 
The functionality is being rolled out within a Health Trust in the East of England.  The company now wishes to find a national / regional opportunity that would benefit from a single system to promote trials.
What is the intellectual property status of your innovation?:
Released.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
Sandie Shokar 30/08/2018 - 16:55 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Enabling patients to self-rehabilitate with clinically evidenced treatment plans to improve the speed of recovery and enhance patient outcomes. Reducing unnecessary prescription of medicines, scans and surgery; along with GP and Physio workloads.
 
Overview of Innovation:
Rehab Me offers GP’s a tool to help advise and support their patients without necessarily referring them to a physio for a scan or prescribing pain medication. It provides easy to access evidenced based advice sheets, treatment plans and interactive prompts to support compliance and outcome tracking, as well as signposting patients to further support and prevention pathways.
 
How it works: A simple digital solution, accesses on-line or via a downloadable all which operates on a stand-alone basis or be integrated into existing GP systems.
 
Step 1 - patient injury or MSK condition identified by GP who then prints off the relevant advice sheet from the Rehab Me website. This provides evidence-based exercises and advice regulated by standard physiotherapy practice and directs patient to the Rehab Me website for the patient to register.

Step 2 - patient registers on the Rehab Me website and selects the treatment plan advised by the GP. This will then provide scheduled exercises including frequency and number of repetitions across the treatment plan period. This is automatically linked to the patient’s calendar to enable reminders and prompts over the treatment period which can be anywhere between 6-10 weeks.
 
Step 3 - the patient can access the plan via the website or a downloadable app. The patient will be prompted each day and guided by their virtual physio with the use of easy to follow HD videos and/ or detailed descriptions.  Patients track their own adherence and progress through the website or via the app. They can also record and track pain each day to help assess progress and provide PROM data for their GP.
 
Step 4 – at any time the GP can view progress and results for a patient on a treatment plan; and if appropriate advice on a new exercise plan virtually so the patient can progress without the need for another appointment.
 
Step 5 – during or after a course of treatment, Rehab Me can signpost access to other relevant resources to encourage people to adopt exercise into their everyday lives to prevent relapse. This includes a social prescribing section encouraging patients to join gyms, walking clubs etc.
 
Part of the service provided by Rehab Me includes educational training on MSK issues as part of the process to this new pathway for GP’s to adopt in their practice.

The Rehab Me data platform adheres to appropriate NHS data IG and GDPR requirements, with all data securely stored on a cloud based server.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
The Rehab Me solution has been proven to:
  • Reduce unnecessary prescription of medicine
  • Reduce the need for costly scans and potential surgery
  • Reduce demand on physio appointments
  • Improve a GP’s ability to provide relevant MSK advice
  • Improve patient activation and compliance
  • Improve waiting times for specialist physio appointments
  • Support First Contact Practitioners in GP surgeries.
 
There is further opportunity for Rehab Me to reduce demand through earlier preventative treatment, on-going self-management support and improvement in post-surgery recovery and potential length of stay in hospital.
 
The results: a structured 18-month proof of concept across five GP practices servicing c70,000 people resulted in 2300 patients being supported, achieving the following key results.
 
  • 89% of GPs said they are now ‘confident’/ ‘extremely confident’ in managing MSK issues, versus 33% at the start
  • 70.3% of GPs recommended over 50% of patients to Rehab Me rather than referring to a physio.
  • 30.8% of GPs reduced prescribing medication by 50%
  • 25.9% of GPs reduced referral for imaging (XR, USS, MRI)
  • 19.2% reduced prescribing medication by 70% for MSK conditions
  • 50% improvement in patient pain scores, average score of 3/10 to 6/10
  • 66.7% of GPs rated the pilot 10/10 (with 10 = fantastic)
  • Reduced physio waiting times, from over 7 weeks to just 2 weeks for patients
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
For Patients
  • Immediate and faster recovery time
  • Improve health, well-being and pain management
  • Increased confidence and empowerment to re-habilitate.
  • Reduced inconvenience and travel time for appointments
  • Avoid risks and side effects of anti-inflammatories, analgesics or other medications    
  • Potential surgery avoidance or painful injections
  • Easy and convenient solution access.
For GP’s
  • Increase knowledge and confidence to support patients with MSK conditions
  • Reduction in prescribed medicines
  • Reduction in physio referrals
  • Reduction in imaging and consultant referrals
  • Reduction in GP appointments
  • Ability to track patient activation and PROMS
  • Increased practice efficiency.
For NHS Physiotherapy clinics and other referral departments
  • Reduced number of referrals
  • Reduced wait times to enhance intervention effectiveness
  • Improved prioritisation of serious patient referrals
  • Enhanced quality of service and care
For Commissioners
  • Better resource utilisation
  • Increased capacity at lower cost
  • Alignment to the GIRFT programme
  • Strong ROI based in increased capacity and reduced medication / scan costs
For the Economy
  • Local employment - potential to build software development team locally
  • Local office - commercial office space
Current and planned activity: 
The Rehab Me solution has been supported By NHS England through its Clinical Entrepreneur programme and identified by Dr. Tony Young, (National Clinical Lead for Innovation) as a lead example of a new and exciting digital solution for scaling across the NHS.
 
The Rehab Me platform has been developed to Beta release level and is now ready for further development to ensure a robust and scalable software solution which can be easily integrated into other NHS systems.
 
The next stage requires effective engagement with appropriate PCN or GP Federations or CCG to secure financial commitment to embed the solution, support its development and assist in further case study creation and cost benefit analysis. This will then enable a comprehensive sales and marketing drive across England.
What is the intellectual property status of your innovation?:
Copyright of all content owned by Surrey Physio along with software design
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Mark Doorbar 13/05/2019 - 09:41 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
A complete holistic digital outpatient care platform which enables healthcare service providers to offer virtual care remote patient monitoring.
Overview of Innovation:
VideoVisit provides a complete holistic digital outpatient care platform that enables healthcare service providers to offer virtual care (i.e. home care and rehabilitation services), remote patient monitoring, online doctor consultation and video-based online doctor appointments via online calendar booking systems or text chat/video chat module. Complete holistic digital outpatient care can be defined as combining Primary Care, Social Care, Specialized Care and Home Care. We offer full end-to-end systems branded under VideoVisit Home Care and VideoVisit Remote Care service products.



The platform consists of tools for remote care, online doctor appointments / consultations and remote patient monitoring. Virtual care allows remote caregivers to provide healthcare services, support and companionship to the elderly in their own home via video.

Online doctor appointments allow healthcare service providers to offer services online either by utilizing a chat module with text-chat and video chat functionality or by providing video-based services via online calendar booking system. Online doctor consultation allows healthcare professionals to communicate together both through more traditional text-chat or via online video calls.

Remote patient monitoring puts together welfare devices and services and shows what is going on at home at this very moment. Using the dashboard, family members, homecare professionals and service providers see in real time the summary of how the person living at home is doing. It shows for example activity, sleeping patterns, day rhythm and information about safety and service usage.

Our platform can be sold as a stand-alone solution or it can be integrated into other digital healthcare solutions. This provides endless possibilities for VideoVisit partners to utilize VideoVisit platform. In addition to VideoVisit platform, we also provide our know-how on distributing the VideoVisit platform to end customer organizations. We also provide the best references in the market for our partners: we are the only service provider who has a whole country as a reference testimony (Finland) and a customer case where cost savings in elderly care have dropped over 85% (City of Helsinki): https://www.youtube.com/watch?v=sI628Mj5UaM

VideoVisit is the market leader in Finland with a fully commercialized service offering. In the UK we are seeking a Proof of Concept trial partner to make any adjustments required and to show the value of our solution.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
VideoVisit is a market leading Nordic health technology company, developing digital solutions for the home care and healthcare sectors. The VideoVisit platform consists of two modules; VideoVisit® Home and VideoVisit® Live, which together provide a unique virtual healthcare platform.

The benefit to the NHS from our service solution is our impact on:

1) Cost savings – substantial savings by replacing physical visits with remote caregiving visits via video. As an example, one of our largest customers, the City of Helsinki placed over 170,000 virtual calls while cutting down home care costs by over 80%, saving 10M€ in 2017.

2) Time savings of the healthcare professional (nurse or doctor or service provider) - one virtual nurse is capable of placing up to 60 virtual visits over one shift. The demand for virtual care grows rapidly in Helsinki which illustrates Helsinki’s goal of having over 900 virtual care clients at the end of the year 2017.



Our unique advantages are integrated services, tested outpatient care service platforms, experience and knowledge of outpatient care processes and models. With our platform, we can connect medical device data during video consultations and have system APIs that support this. As the market leader in Finland, we have completed over 50 projects in Finland.

In addition to that, our solution shows increasing value when used with patients who are elderly or with chronic illnesses like dementia, Alzheimer’s or Parkinson’s. As the majority of the elderly and chronic illness patients have restrictions and need support to take medicine and monitor food intake, this can be done cost and time effectively with the VideoVisit solution.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The benefits we can provide to the population of West Midlands are similar to the impact shown above in terms of cost and time benefits.

The West Midlands is a region of diversity, with areas of affluence and deprivation and with established health inequalities. It's a geographically diverse region, ranging from the intensley urbanised areas including Birmingham, Stoke-on-Trent and Coventry to the rural counties including Shropshire, Staffordshire, Herefordshire and Worcestershire.

Online Consultations are part of the Midlands and East GP Forward View (GPFV) Digital Implementation Strategy.

Virtual consultation service benefits include:
  • Cost savings
  • The ability to see multiple patients over one shift
  • Minimises travel for patients (family and carers)
  • Improves networks between doctors, patients and other healthcare professionals
  • Encourages self-care
  • Reduces risk of healthcare associated infections
Video consultations can overcome geographical boundaries and provide access to services in remote areas or those with limited numbers of healthcare professionals.

VideoVisit, a market leader in Finland that provides holistic remote caregiving are looking to work with a regional healthcare provider to undertake a Proof of Concept trial to make any adjustments required for the UK and to demonstrate the value of our proven solution with elderly people and/or for those with chronic illnesses.

Current and planned activity: 
VideoVisit Ltd is actively looking to engage with regional healthcare providers for reference Proof of Concept pilot projects.

We have only just started in the UK and are keen to engage and discuss with any interested NHS or other healthcare service providers working with us to make any adjustments required for the UK and to demonstrate the value of our proven solution with elderly people and/or for those with chronic illnesses..
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Michael Haralson 18/03/2019 - 19:22 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
QxMD is a company dedicated to creating point-of-care applications created by for healthcare professionals, with a global community of 1.9 million clinicians, medical students, scientists and researchers and are free to download and use at any time. 
Overview of Innovation:
Healthcare professionals need to stay up to date on the latest medical research and topic reviews to provide optimal care. Unfortunately, the process of content discovery is broken with research artificially compartmentalised by publishers and hidden behind countless institutional paywalls.

At QxMD, we believe that knowledge translation– the process by which new knowledge is incorporated into clinical practice – is an important and unsolved challenge for our health care system. Read uses smart algorithms to ensure that each and every user has a dedicated newsfeed of research that applies to their practice. 
With Read, Institutional Edition, organisations can seamlessly integrate their existing journal subscriptions and existing proxy service to provide a platform for their clinical staff to access content which matters to their individual practices. It is built with features designed to improve patient care and reduce costs. 

The Promoted Research feature is used by institutions who want to disseminate research that impacts areas of care the most within their organisation. For example, a Hospital with high rates of Sepsis can use this tool to promote guidelines that reduce Sepsis cases with higher guarantees their clinical staff will discover the research and apply it to the next patient. 

Librarians and Knowledge Managers can take advantage of smart analytics to understand which journal subscriptions are performing the best and worst and also which journals are most popular, which they don't subscribe to.

NHS Trusts are already adopting QxMD, with over 100,000 users in the UK alone. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Better educatad and up-to-date staff, specific to their practice
  • Cost saving on journal subscription costs
  • Improved patient care
  • Challenges identified and tackled via the Promoted Research feature
  • Easy to discover and access research from any smart device
  • Links with OpenAthens for instant access to subscribed content. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
  • Better educated healthcare professionals who can identify the latest research and apply it to patient care
  • Less chances of mis/under diagnosis, readmission or even death
  • Improved quality of care
Current and planned activity: 
  • Existing NHS Trust clients, including the largest Mental Health Trust in the UK
  • Continue to grow our userbase, which is already at 100,000 UK users, with the support of Trusts and other stakeholders. 
What is the intellectual property status of your innovation?:
  • We have designed and developed the platform entirely in-house. No white-labelling. A completely unique tool built by Healthcare Professionals for Healthcare Professionals. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Jimmy Connoley 19/06/2018 - 12:56 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Sensium Wireless Vitals Monitoring is proven to lead to treatment of sepsis 6 hours quicker than NEWS, reduce LOS by 10% and readmission by 45%. The only wearable vital sign monitor with peer reviewed RCT data showing significant clinical benefits. 
Overview of Innovation:
In general care areas of a hospital vital signs are typically taken during routine observation rounds once every 4-8 hours. If a patient deteriorates between these observation rounds the warning signs can go undetected for hours, potentially leading to serious & costly consequences. 
 
Sensium is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. A light comfortable sensor worn on the patient’s chest accurately and reliably monitors and reports vital signs, providing data every 2 minutes. By notifying clinicians of changes in patients’ vital signs Sensium brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, thereby improving patient outcomes, shortening hospital stays and lowering treatment costs. It enables nurses to prioritise patient care where it is needed most.   Sensium is focussed exclusively on general care clinicians whose patients currently do not have the safety and security of continuous vital sign monitoring.
 
The Sensium Patch provides accurate and continuous monitoring of the 3 key leading indicators of patient deterioration: heart rate (HR), respiration rate (RR) & axillary temperature (T). Sensium wirelessly communicates this physiological data via safe and secure low power wireless communication to the Sensium bridges placed through the ward area.  Sensium allows patients to ambulate freely, untethered to static and expensive equipment whilst still having the reassurance of continuous monitoring.
 
The bridges are connected into the hospital IT system, and software installed on the hospital network allows patient data to be seamlessly conveyed. Crucially, notifications can be configured to work with hospital pager systems/mobile notification devices, giving the clinical team data when they need it, where they need it. To save time and ensure accuracy Sensium can be easily integrated with the hospital admission, discharge, transfer systems and electronic medical records.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Currently approximately 10% of patients are harmed during their hospital stay and this represents a cost to the NHS of over £2.5bn just to cover the additional length of stay for these patients. Improved monitoring regimes and early detection of deterioration is key to reducing this significant burden.
 
Patients undergoing major abdominal surgery have an 30-40% risk of complications with a leading complication being sepsis. Hospital acquired (HA) sepsis (e.g. sepsis that develops after a surgical procedure) has twice the mortality rate and twice the treatment cost of community-acquired sepsis and rates of HA sepsis are rising. A recently-published study aimed to assess differences in outcomes between patients being monitored using the Sensium system in addition to intermittent (routine) observations and patients being monitored by routine observations alone [1].  The study was designed as a pilot cluster-randomised, prospective, parallel-group, controlled single-centre pilot study and consenting participants were allocated to one of two monitoring arms for the length of their admission. The primary outcome measure was time to antibiotics after the first evidence of sepsis, defined according to a revised consensus conference definition in 2001 [2]. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. There were a similar number of complications and sepsis events across both arms of the study, indicating that both groups had similar baseline risk factors.

On average, patients receiving Sensium continuous monitoring were administered antibiotics 6.4 hours sooner after evidence of sepsis, had a 10% shorter average length of hospital stay and were 45% less likely to require readmission within 30 days of discharge than those patients in the intermittent monitoring group. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety. Given that every hour’s delay in treatment of sepsis has been shown to be associated with a 7% increase in risk of mortality [3], a 6-hour reduction in time to administer antibiotics is a significant result and further studies are ongoing to demonstrate similar benefits in other clinical settings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Sensium’s solution offers several key benefits to the West Midlands and its population. The key benefits of Sensium compared to competitor products are as follows:

Product Performance: Sensium uses clinically accepted ‘gold standard’ methods of vital sign measurement, deriving heart rate from single-lead ECG, respiration rate from thoracic impedance, and temperature from an axilla sensor.  In contrast, our competitors derive respiratory rate from pulse or ECG measurements which has known limitations in certain clinical conditions and provide only skin temperature measurement which has limited clinical value.

Customer Focus: Sensium is recognised by our customers for exceptional customer support.  Once we deploy our product at a clinical site, we provide on-site technical support for installation and troubleshooting and clinical support for training for as long as it takes for the system to be truly embedded in the clinical workflow and providing tangible benefits. Sensium has clinical and technical staff based in the West Midlands region on hand for support.

Clinical Evidence: Sensium understand that medicine is an evidence-based science and we are engaged in a series of clinical research studies designed to show clinical efficacy, improved clinical outcomes, and health economic benefits.  To date, Sensium are the only company providing wearable wireless technology for early detection of patient deterioration that have independent and peer-reviewed publications showing benefits of our technology demonstrated through randomised controlled trials
 
 
Current and planned activity: 
Our initial engagement with the NHS has been to introduce Sensium to general surgery wards and areas with high risk and infection prone patients e.g. colorectal, trauma and haematology wards. Discussions with many NHS hospitals have also shown significant interest and benefit for the use of Sensium for ‘Step down’ areas for patients who aren’t sick enough for ITU but still show cause for concern and for high risk conditions such as Hospital Acquired Sepsis opioid depression and AF. 

We have engaged with the Emergency Laparotomy Collaborative with a view to patch these types of patients. When approaching the NHS, we have been primarily engaging with Anaesthetists as they witness many patient deteriorations, as well as consultants and sepsis/patient deterioration leads, matrons and clinical IT leads. We plan to interact more directly with medical directors and members of the directorate earlier on in the process if possible. Future plans include home monitoring to follow patients’ home.
What is the intellectual property status of your innovation?:
CE mark and FDA 510(k) cleared.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
2
Co-Authors:
Read more
Hide details
Sonia Hussein 18/05/2019 - 11:34 Publish 4 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Detection of acute, chronic and very early stage diseases in real time based on tests results and alerting all authorized parties about detected problems with of the essential patient information on mobiles, tablets and computers.
Overview of Innovation:
As it could be integrated and is constantly receiving data from current lab and EHR systems, it immediately detects problems in lab test results and informs doctors about new lab data received and issues detected for a particular patient. It gives access to historical data with some valuable statistical calculated and visualised data which helps doctors to understand acute, chronic, hidden or early stage health problems over secure web/mobile/tablet applications, so doctors can see these results for making better and correct decisions any time and in any location they are in at any moment.
 
Core applications of the solution are:
1. Speeding up doctors’ workflow in hospitals. At the moment, doctors in NHS have to go to rooms where there are computers with access to lab data. Quite often, doctors spend time waiting for each other to get access to their patient blood test data.

An essential part of the solution is the mobile/tablet application which can be installed on any mobile operation system iOS/Android. Which lead to:
  • Freeing up to 2 hours of doctors’ time daily
  • Increasing patient turnaround time on average by 25%
  • Increasing time reaction on most critical acute cases up to 99% 
2. In Doctors’ practice, there have been cases when a delay in days, hours or minutes in getting lab data in time is crucial for a patient’s life.  

Platform is constantly tracking blood data from the lab system, it analyzes it and alerts about critical changes in lab tests metrics and it immediately sends notifications to related parties to pay attention on a particular case.

At the moment, it tracks more than 25+ diseases and all other blood test parameters and (early and acute): AKI + CKD (all types), Sepsis and much more.

3. Platform provides historical analysis tools for blood results and gives some related insight information for each particular test parameter, so it is quick and easy to see the problem and identify potential problems at a very early stage and apply preventive actions to avoid problems. 

4. Platform has a recommendation system which seeks potential hidden problems in results. If those potential hidden problems are found, the platform gives an explanation and list of additional tests required to confirm potential problems.

5. For management team it provides deep business insight (visulised with over the time progression) of a difference scale: Hospital, Groups of Hospitals and National level about detected problems, about performance of laboratories, doctors and etc.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential impact of the Pin.Health on NHS
 
Product results in efficient improvements:
—  Increases time reaction on most critical acute cases up to 99%, that decreases the amount of fatal cases in hospitals
—  It frees up to 25% of doctors and GP’s time daily
—  Increases patient turnaround on average by 25%
—  Saves money on unnecessary blood tests and use of hospital beds

Product results in cost improvements:
—  It saves more than £18,000.00 GBP per doctor per annum
—  Decreases amount of unnecessary admissions up to 25%
—  Increases revenue up to 20% with the same medical headcount for commercial healthcare companies
—  Decreases the amount of unnecessary sales and blood test results in labs
—  Significant healthcare budget decrease on investment in huge IT project
 
Product results in patient care improvements:
—  Increases time reaction on most critical acute cases up to 99% that decreases the amount of fatal cases in hospitals
—  Early stage disease identification with more than 95%+ accuracy rate, and it keeps growing. It prevents serious illness conditions — move focus to preventative medicine
—  Decreases amount of fatal cases at the Hospital
—  Decreases number of doctors’ errors or human factors
 
Pin.Health supports the HSCIC Strategy (NHS Digital) 2015–2020 Strategy as well as some general European Union Strategies in Healthcare.
  1. Ensuring that every citizen’s data is protected
    Platform follows HIPAA, GDPR and UK Law in relation to data access and protection. 
  2. Establishing shared architecture and standards so everyone benefits
    Platform has API based on industry-standard protocol FHIR HL7 (JSON based protocol). Any trusted (pre-authorized by NHS) 3rd party applications and systems can connect to Pin.Health over a secure connection over API and get access to data it has, and results it has produced. 
  3. Implementing services that meet national and local needs
    As platform provides access to data and results it produced over API — any external trusted applications/systems can be built on top of it to solve other problems.
  4. Making better use of health and care information
    Pin.Health solves numerous problems which helps improve workflow in hospitals, speed up process of disease identification to save patients’ lifes and to avoid critical conditions, moving the focus to preventive medicine, proceed researches based on data platform aggregates. All of it implements better use of health and care information.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
In some doctors’ practices, there have been cases when a delay in days, hours, or even minutes in getting lab data in time is crucial to a patient’s life. Our platform solves this such challenges.

The platform is monitoring data from 3 perspectives — first it’s trying to detect acute diseases, after it recognizes chronic conditions and early stage conditions for each newly received test.
 
At the moment, we are tracking more than 25 diseases such as Acute Kidney Injury and Chronic Kidney diseases of all types, Anaemia of all types, Liver Disease and others, as well as all test parameters, whether they are out of range or not, and if they are at a chronic stage or an early stage.
 
One example is the AKI (Acute Kidney Injury) which is one of the diseases that is tracking in our system. AKI is a sudden and recent reduction in a person’s kidney function.  Despite the high incidence, AKI in hospitalized patients is characterized by a high rate of missed diagnosis. The missed diagnosis rate is about 57% even in high-income countries. In the UK, 1 in 5 emergency admissions into the hospital are associated with AKI, with up to 100,000 deaths each year in hospitals associated with acute kidney injury. From official UK NHS statistics, up to 30% could be prevented with the right care.

All in all platform leads to NHS operational, financial improvements as well as in longer and stronger health of the West Midlands population.
Current and planned activity: 
We would be interested in running the pilot project with one of the NHS Trust or Hospital for a period of 2-4 months. Afterwards, integration will be completed. To gather statistic about platform performance and getting first feedback from clinical environment, which leads to futher platform improvements and scaling benefits which platform gives over other NHS Trusts.
What is the intellectual property status of your innovation?:
Company is IP holder of the solution.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 05/12/2018 - 00:09 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Hospify is a health data platform built on free & trusted messaging for patients and clinicians. A free messaging app is available to all users; a team messaging platform is sold to hospitals, surgeries, pharmacos and other healthcare institutions.
Overview of Innovation:
  • Hospify is an ubiquitous health comms ecosystem that puts patients & clinicians in control of their health interactions in a way that everyone can access and trust
  • Hospify allows patients to connect with and control their communications with healthcare providers, pharmacists, pharmacos and insurers
  • Like Slack in the commercial sector, Hospify uses open standards to enables other health apps and digital services to function within an ecosystem that benefits all parties involved
  • Hospify’s unique “serverless” phone- powered network architecture allows it to scale users without scaling costs while staying compliant with all data regulations.
     
There are lots of healthcare messaging companies popping up. So what makes Hospify different?

1) A messaging platform is only useful if everyone can be on it. That’s why people love WhatsApp. For everyone to be on it, the core platform has to be free. Hospify is built on a unique serverless architecture that allows it to scale the app without scaling the costs of supporting it.  This allows Hospify to offer its core messaging, for free, to everyone, forever, without needing to monetize our users’ data or sell them ads in order to do it. 
2) That serverless structure means that we don’t store users’ data (one of the reasons that we can’t monetize it!). All the data, at least in the free, secure and compliant app, is kept on the user’s device, and only on the user’s device. This means that compliance is baked in from the start, and enormously reduces data liabilities and security overheads - which in turn helps support our ability to provide the app for free to the majority of users.
3) Hospify is really simple to use. Most of our competitors are building complicated messaging tools designed to appeal to doctors. But at Hospify our focus is on nurses and patients - the people at the sharp end of health, who want solutions that are simple and effective and don’t require a manual in order to them figure out.
4) The Hospify messaging app is only part of what we do. Hospify’s secret weapon is the HospifyHub. The Hub transforms the App’s “WhatsApp”- style experience into something that’s more like Slack, with a web portal and a desktop app that syncs with users’ phones without compromising our compliant and scalable “serverless” architecture. The Hub offers administrated groups, broadcast messaging, and data capture via messaging surveys, and is designed to integrate with and handle data from third-party apps.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Efficiency gains from simple, non-siloed comms
Reduced risk of data breach and better clinician & patient privacy
Reduced time to decisions
Fewer face-to-face follow-ups
More timely interventions
Improved patient-centric care  
Improved mobile working
Improved interdisciplinary and inter-organisational working
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
Easier access to clinical professionals
Reduced travelling to appointments
More control over personal health data
Reduced risk of health data breach
Less frustrated clinical staff!
Reduced spend at CCG level on SMS
Current and planned activity: 
Traction (App)
  • Hospify’s free messaging app is live in the Apple & Google app stores with more than 4000 sign-ups across 60 hospitals since launch in Feb ’18 and 25% monthly active users.
The Hospify App is secure and compliant for health use across the UK and EU. End users can download the FREE Hospify App via the Apple and Android app stores.  

Live Trials (Hub)
  • Unison Health: paid trial at University Hospitals North Midlands. Intention to scale out nationally to >1k branches and >500k nurses
  • Birmingham Community NHS Trust: free trial
  • Cambridge & Peterborough NHS Trust: free trial
  • Lincolnshire Community NHS Trust: free trial
  • Medway Community NHS Trust: Up to 900 users for 3 months’ free trial
  • Corby NHS Health Centre (Lakeside+): 90 users for 3 months’ free trial The GP Service: telehealth company with national reach
 
 
What is the intellectual property status of your innovation?:
UK trademarks filed; EU, Colombia & US trademarks in process.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regulatory Approvals:
When designing its message delivery and information security architecture in 2015, Hospify carried out detailed discussions with the Information Commissioner’s Office about the legislative landscape around secure messaging in health. As a result, Hospify combines cutting edge technology and powerful security with careful consideration of UK and EU rules for handling patient information, and has the following accreditations:
  • GDPR & 2018 UK DPA compliant
  • NHS IG Toolkit (2017-2018) & DSPT (2019) (Org code: 8JN92)
  • Crown Commercial Service supplier (GCloud 11)
  • ISO 27001:2017 accreditation (Registration number: 214722)
  • ICO registered (ZA239336)
  • US encryption export registered (SNAP-R ERN R11191)
 
Read more
Hide details
James Flint 11/03/2019 - 14:39 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Modul-Bio provides a biological data management software specifically designed for biobanks and cohort projects. Main functionalities include patient management, samples collection, processing, distribution and disposal.
Overview of Innovation:
MBioLIMS BioBanking®
 
Modul-Bio solutions allow users to manage the complete lifecycle of biological material and related data. MBioLIMS BioBanking® is dedicated to the management of samples and associated data and is modular and evolutive allowing the expansion and fit of the system to match laboratory requirements..
The whole system is intuitive for end-users, flexible for customization, easily scalable even in a multi-site environment, accepts plug-ins for applications or equipment such as laboratory instruments, robotics or storage, and ensures long term data security.

Access to the application is via a local Browser with no installation required on individual computers. The setup of the system facilitates confidentiality with secured data transmission on HTTPS, and is VPN compatible. MBioLIMS BioBanking® can be installed locally, or as a cloud solution to fit client needs.

It is possible to specify the level of access of each user by creating new profiles with specific roles. It is also possible to show/hide nominative data. Each site can have an internal administrator, trained by Modul-Bio’s team to manage and evolve the solution as required.

A complete Audit Trail is embedded within MBioLIMS BioBanking® which records all actions taken including user registration, who performed the action (create, modify, delete), date and time, fields and values that have been modified. This covers sample movement, transformation to end points such as destruction to provide traceability and information that can be used in reports, audits and business improvement.

Sample storage and movement is fully monitored and storage containers can be designed and edited by system administrators. This allows the client to replicate the laboratory space within the system, monitor and report sample movement and custody. Storage can be assigned to certain studies, or restricted to particular sample types to prevent incorrect use of space. If samples are transferred to other facilities, or external contacts the shipment and manifests of these activities can also be created and controlled within the application. The interface provides a visual representation of the storage system that allows users to navigate all freezers, nitrogen tanks as well as their content all the way to the details of the sample container (tube/plate/2D rack, etc.)

Many other modules are available, and more are developed each year to match biobank requirements.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
MbioLIMS provides a specific solution for biobanking laboratories and projects. This facilitates the management of the patient and sample data, and generates viable sample / metadata for research. It can also be connected to eMBIOBANK, a web catalogue for research use.
NHS data can be stored securely, or held outside of the MbioLIMS application and linked by an anoymous unique identifier. In either case, samples and derivatives are linked to the information required.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Modul-Bio is commited to providing a benefit to all client locations, but has resource locally to the West Midlands.
Current and planned activity: 
MbioLIMS is already used in the UK, with NHS data integration as needed. Modul-Bio is continuing to expand both UK and International clients with the required connection to patient registeries.
The application is designed to improve biobank management, sample custody and viability to promote more utilisation and research for increasing patient well being.
What is the intellectual property status of your innovation?:
The Software and any authorized copy are the intellectual property, the valuable trade secrets and confidential information of the Service Provider who owns the relevant rights. The Software is protected by law, including without limitation the copyright laws of France and other countries, and by international treaty provisions. The Service Provider does not assign any property right when licensing its software solutions and reserves all rights not herein granted. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
MBioLIMS has an available compartmentalisation module which is designed for scalability across regions (or even countries) so that different laboratories can access the same instance when working together.
Modul-Bio has previously implemented solutions within the same regions and once inbedded can facilitate user groups and collaboration.
Measures:
Modul-Bio has designed MBioLIMS to improve biobank processes, sample custody and managment. The system is focused on faster and more thourough management and processing. We do ask current clients for reviews and identified ROI's.
Adoption target:
Target clients are hospitals, universities and private organisations that host a biobank.
 
Read more
Hide details
Mike Woodward 01/07/2019 - 12:27 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Amplitude pro enterprise™ uses simple technology to capture clinical and outcome data for specific diseases, diagnosis, interventions and care pathways. Data is retained locally and available for immediate reporting and analysis.
Overview of Innovation:
The Amplitude pro enterprise™ software is a simple, tailored online platform centred around two crucial elements:
A user-friendly electronic patient portal which gives patients the freedom of completing their scores online at home, on site and via various devices and a consultant dashboard giving the clinician(s) the ability to input patient specific complexity factors and procedure data quickly and easily.

The result is representative, accurate and meaningful data that paints a clearer picture of each patient’s level of health and expected recovery. Clinicians are engaged with the clinical outcomes processes at your hospital, you get the insight required to innovate your clinical services and patients get a consistently high standard of care.

pro enterprise™ is simple, cost effective and delivers precise and accurate data, selecting scores that are identified as important to you.

The data you collect in pro enterprise™ will allow you to monitor your service delivery, identify quality issues and demonstrate levels of care. Your hospital can be confidently transparent about its activities, resulting in reassurance to your peers that you are offering the best care possible.

Amplitude specialises in the collection of electronic PROMs and clinical outcomes and we are the leading supplier of electronic PROMs to the NHS. We are accredited by NHS Digital for the electronic capture and upload of National PROMs and our platforms have achieved the highest levels of IG compliance, using data centres that are ISO27001 certified. 

Amplitude's unique data exchange tool means that you enter and retain your data locally in your pro enterprise™ platform and the necessary data for clinical registries, National PROMs and NJR can be  pushed to the relevant databases on your behalf.

Our systems are designed to empower clinicians in adding value to their data e.g. proper case mix adjustment, log-book, revalidation report and easy analysis and self-monitoring tools. The system automates the process of data collection via a series of reminders sent to patients via email and SMS. These reminders are triggered from the intervention data which at minimum includes procedure/intervention description and diagnosis. 

Amplitude pro enterprise™ is customised and tailored to suit specific department requirements and objectives including virtual clinics, clinical outcomes and PROMs. pro enterprise™ is currently being used in T&O, Rheumatology, Urology, Cardiology and Mental Health departments.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Amplitude pro enterprise™ system captures and manages clinical and PROM’s outcome data with the key focus to improve overall quality of patient care.
NHS healthcare professionals are required in many specialist areas, to monitor the long-term effects of treatments.  Historically, these were captured on a macro level and this mass gathering of non-specific data, results in outcomes data that is non-meaningful and without sufficient detail or context, preventing its use in making effective, informed clinical and management decisions.
In addition, due to the paper-based nature of how PROM’s and clinical outcomes were historically gathered, often, data would only be made available months after being gathered and in an aggregated and anonymised format, rendering it out of date and of little value.

With Amplitude pro enterprise™, The NHS benefits from the ability to;
  • Capture the clinical outcomes of patients in larger numbers and in an electronic format,
  • Effectively measure the quality of care provided by clinicians in real-time
  • Measure the efficacy of the treatments being used on a local, national and international level
  • Reduce costs associated with carrying out the required questionnaires in a paper format
  • Use the data gathered to compare treatment plans and ensure that patients are receiving the best possible care available
  • Increase clinical and patient compliance and engagement in outcome data collection
  • Meet the challenge to make the NHS paperless
  • Opportunity to provide multiple language options; allowing the patient to complete their electronic questionnaires in their native language instantly
  • Use Amplitude's unique data exchange tool to automatically upload required registry data when the information is gathered in the Amplitude pro registry™ platforms, thus reducing administration, duplication of effort and importantly, retains the outcomes data at the source pro enterprise™ system, allowing instant insight
  • Access to comprehensive reporting tools, that include templated validation reports for individual clinicians, further reducing resource, time and effort
Amplitude pro enterprise™ provides the NHS with a paperless, streamlined data gathering software, that reduces costs, has real-time results, meaningful insights for clinical and managerial decision makers and ultimately improves the overall quality of patient care.
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
The West Midlands AHSN covers 6 regions within the NHS; Birmingham and Solihull, The Black Country, Coventry and Warwickshire, Herefordshire and Worcestershire, Shropshire and Staffordshire.

Within this area, there are 33 NHS Trusts servicing the needs of a population of approximately 7.225 million (ONS 2017). According to the ONS, 18.2% of the population were aged 65 years and over.
It is also documented that over half (54%) of older people have at least two chronic conditions increasing to 69% among those aged 85+ (Kingston, et al., 2018).
Multi-morbidity increases the likelihood of hospital admission, length of stay and likelihood of readmission, raises healthcare costs, reduces quality of life, and  increases dependency. (Kingston et al., 2018).

These are all operational factors being faced in the West Midlands region and the implementation of innovative technologies, to help manage the growing dependency on the NHS, are essential.
The implementation of Amplitude pro enterprise™ will not only allow for monitoring outcomes, it can also use the outcomes data to manage workloads, triage clinics and help to influence operational management. 

Eg; fracture clinics see all patients admitted to A&E with musculoskeletal problems, the system could reduce the number of follow up appointments in Trauma and Orthopaedics clinics by assessing cases in a virtual clinic, prioritising the appointments of patients that require surgery or a clinic appointment and booking those that are less urgent into follow up clinics.

Or: The Amplitude pro enterprise™ platform can provide the method of prioritising more urgent cases in Rheumatology or Cardiology clinics, allowing urgent cases to be seen ahead of patients who are performing well with their current ongoing treatment plan.

Managing the patients according to need and not by pre-set time frames, could help to prevent potential A&E visits by patients who deteriorate or do not respond as expected to their treatment plans.

Administrative workloads can be reduced, and the overall quality of care provided to patients can be dramatically improved, whilst overall cost savings are obtained as a result.

In addition, administrative productivity can be increased with the data exchange tool. For mandated registry data submission such as National PROMs, NJR and now BSR (Apr 2019), data is entered just once and the Amplitude pro enterprise™ platform uploads the relevant information as required, with the data being retained for local analysis.
Current and planned activity: 
With a wealth of NHS experience in the Amplitude team, the products we design and develop have NHS priorities and needs at the heart. When the pro enterprise™ platform is deployed into a hospital or trust, the Amplitude development team continue to improve the system to best service it’s users. Upgrades are released annually, upgrading the functionality on a regular basis.

CCG’s are looking at commissioning based on outcomes and lucrative contracts are sent to the trusts and hospitals with the best results. pro enterprise™ ensures boards can evidence their results to win these contracts, adding funding to budgets.

pro enterprise ™ promotes interoperability. The ability to receive data via exchange from a growing number of PAS’s is a major factor in reducing administrative workload and costs, but when this technology is combined with the ability to also push the data (electronically) to populate the associated registries too, the benefits and cost reductions are multiplied.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes own the intellectual property rights on this platform.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 16/04/2019 - 10:58 Publish Login or Register to post comments
0
0
Votes
-99999

Active Campaigns